Research programme: HMG CoA reductase inhibitors - Tel Aviv University

Drug Profile

Research programme: HMG CoA reductase inhibitors - Tel Aviv University

Alternative Names: HMG CoA reductase inhibitors research programme - Tel Aviv University

Latest Information Update: 18 Feb 2008

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Ramot at Tel Aviv University; Tel Aviv University
  • Class
  • Mechanism of Action HMG-CoA reductase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Skin disorders

Most Recent Events

  • 20 Dec 2005 No development reported - Clinical-Phase-Unknown for Skin disorders in Israel (unspecified route)
  • 04 Apr 2001 This programme is available for licensing (http://www.tau.ac.il/ramot)
  • 04 Apr 2001 Investigation in Skin disorders in Israel (Unknown route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top